GSK PLC Receives FDA Approval for Benlysta Autoinjector
GSK PLC, a pharmaceutical company in the Health Care sector, has received FDA approval for its Benlysta Autoinjector for lupus treatment. The approval was granted on [date], marking a significant development in the field of medicine.
FDA Approval Details
- Product: Benlysta Autoinjector
- Indication: Lupus treatment
- Approval Date: [date]
- Regulatory Body: US Food and Drug Administration (FDA)
Company Developments
GSK PLC has also faced criticism for its decision to discontinue a widely used asthma inhaler for children. The decision has prompted an investigation by US Senator Maggie Hassan.
- Discontinued Product: Asthma inhaler for children
- Reason: Not specified
Corporate Social Responsibility
GSK PLC has been involved in various initiatives, including joining other big pharma companies in honoring LGBTQ+ Pride month.
- Initiative: Honoring LGBTQ+ Pride month
- Partners: Other big pharma companies
Market Impact
The recent news has had a mixed impact on the company’s stock price, with some fluctuations in the market.
- Stock Price: [current stock price]
- Market Impact: Mixed